We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Greenlights Blockbuster Diabetes Drug Jardiance for Chronic Kidney Disease
FDA Greenlights Blockbuster Diabetes Drug Jardiance for Chronic Kidney Disease
Eli Lilly and Boehringer Ingelheim have secured another FDA approval for blockbuster diabetes drug Jardiance (empagliflozin), announcing that the agency has OK’d the drug for treating adults with chronic kidney disease.